Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Aura Biosciences Inc (AURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: AURA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.2
1 Year Target Price $21.2
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.78% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 430.31M USD | Price to earnings Ratio - | 1Y Target Price 21.2 |
Price to earnings Ratio - | 1Y Target Price 21.2 | ||
Volume (30-day avg) 7 | Beta 0.46 | 52 Weeks Range 4.34 - 12.38 | Updated Date 08/13/2025 |
52 Weeks Range 4.34 - 12.38 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.9 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.467 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.92% | Return on Equity (TTM) -56.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 320763001 | Price to Sales(TTM) - |
Enterprise Value 320763001 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.68 | Shares Outstanding 62004300 | Shares Floating 33094437 |
Shares Outstanding 62004300 | Shares Floating 33094437 | ||
Percent Insiders 1.98 | Percent Institutions 76.82 |
Upturn AI SWOT
Aura Biosciences Inc
Company Overview
History and Background
Aura Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies to treat life- and vision-threatening cancers. Founded in 2009, Aura is pioneering the development of virus-like drug conjugates (VDCs) for targeted delivery of therapies to tumors. Significant milestones include advancing its lead product candidate, AU-011 (belzupacap sarotalocan), into clinical trials for the treatment of choroidal melanoma and securing funding through venture capital and an IPO.
Core Business Areas
- Oncology Therapeutics: Develops virus-like drug conjugates (VDCs) for the targeted destruction of cancer cells.
- Choroidal Melanoma Treatment: Focuses on developing AU-011 for the first-line treatment of primary choroidal melanoma, a rare and life-threatening eye cancer.
Leadership and Structure
Elisabet de los Pinos, PhD, is the President and CEO. The company has a management team overseeing research and development, clinical operations, and business development. The board of directors includes representatives from venture capital firms and industry experts.
Top Products and Market Share
Key Offerings
- AU-011 (belzupacap sarotalocan): A virus-like drug conjugate (VDC) designed to selectively bind to and destroy cancer cells in the eye. Currently in Phase 3 clinical trials for choroidal melanoma. Competitors are limited due to the novel approach, but traditional treatments include radiation therapy and enucleation. Market share is not yet applicable as the product is not yet commercialized. Revenue is currently $0.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, with a focus on targeted therapies and immunotherapies. The specific market for choroidal melanoma treatment is relatively small but underserved, with significant unmet medical needs.
Positioning
Aura Biosciences is positioned as an innovator in targeted cancer therapy, specifically in ocular oncology. Its VDC technology offers a potential advantage over traditional treatments by selectively destroying cancer cells while preserving vision.
Total Addressable Market (TAM)
The total addressable market for choroidal melanoma treatment is estimated to be in the hundreds of millions of dollars annually. With successful Phase 3 trials and commercialization, Aura could capture a significant portion of this market. Other oncology applications for the VDC platform significantly expand the TAM.
Upturn SWOT Analysis
Strengths
- Novel VDC technology platform
- Targeted approach to cancer treatment
- First-in-class potential for AU-011
- Experienced management team
- Orphan drug designation for choroidal melanoma
Weaknesses
- Clinical trial risk
- Dependence on a single lead product candidate
- Need for regulatory approval
- Competition from established oncology therapies
- Limited commercialization experience
Opportunities
- Expansion of VDC platform to other cancers
- Potential for partnerships with larger pharmaceutical companies
- Favorable regulatory environment for orphan drugs
- Growing demand for targeted cancer therapies
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other emerging therapies
- Patent challenges
- Market access and pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- NVS
- MRK
Competitive Landscape
Aura Biosciences competes with established pharmaceutical companies that offer traditional cancer treatments. Its advantage lies in its novel VDC technology and targeted approach, but it faces challenges in terms of commercialization and market access. Aura Biosciences does not yet have a share of the Chroidal Melanoma market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company being in the clinical stage. Growth is primarily reflected in R&D progress and pipeline development.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval for AU-011. Analyst estimates vary widely based on the perceived probability of success. Revenue projected to increase significantly post commercialization.
Recent Initiatives: Recent initiatives include advancing AU-011 through Phase 3 clinical trials, expanding the VDC platform to other oncology targets, and securing partnerships for manufacturing and distribution.
Summary
Aura Biosciences is a clinical-stage company with a novel technology for targeted cancer therapy and a promising lead candidate, AU-011. The company faces significant clinical and regulatory risks, but it has the potential to disrupt the treatment of choroidal melanoma. Its success depends on favorable clinical trial results, regulatory approval, and effective commercialization. Investors should be aware of the high-risk, high-reward nature of this investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aura Biosciences Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | Founder, CEO, President & Director Dr. Elisabet de los Pinos Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.aurabiosciences.com |
Full time employees 106 | Website https://www.aurabiosciences.com | ||
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.